Tacrolimus Appears to Be a Protective Factor for De Novo DSA Formation in Non-Sensitized Kidney Transplant Patients

被引：0
|
作者：
Marron-Wojewodzki, M. [1 ]
Szwarc, I. [1 ]
Rene, C. [2 ]
Mourad, G. [1 ]
Le Quintrec, M. [1 ,3 ]
机构：
[1] Hop Lapeyronie, Dept Nephrol Dialysis & Transplantat, Montpellier, France
[2] Hop St Eloi, Dept Immunol, Montpellier, France
[3] Hop St Eloi, IRMB, INSERM, U1183, Montpellier, France
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2017年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
10
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [21] Racial Differences in Tacrolimus Xr Dosing in De Novo Kidney Transplant Recipients
    Patel, N.
    Carcella, T.
    Bartlett, F.
    Rohan, V.
    Taber, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 818 - 818
  • [22] POPULATION PHARMACOKINETICS AND PHARMACOGENETICS OF TACROLIMUS IN DE NOVO PAEDIATRIC KIDNEY TRANSPLANT RECIPIENTS
    Zhao, W.
    Elie, V
    Roussey, G.
    Brochard, K.
    Niaudet, P.
    Deschenes, G.
    Cochat, P.
    Cloarec, S.
    Andre, J. L.
    Tsimaratos, M.
    Bensman, A.
    Fakhoury, M.
    Jacqz-Aigrain, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 37 - 38
  • [23] Mycophenolate sodium intensified and decreasing dosing regimen in association with tacrolimus in de novo kidney transplant patients
    Delavenne, X.
    Pons, B.
    Basset, T.
    Mehdi, M.
    Maillard, N.
    Sauron, C.
    Bertoux, F.
    Alamarline, E.
    Mariat, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 59 - 59
  • [24] Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated
    Marquet, Pierre
    Anglicheau, Dany
    Humeau, Antoine
    Adrouche, Sofian
    Saada, Lakhdar
    Bisiaux, Julie
    Guillemin, Sara
    Lardy-Cleaud, Audrey
    Rostaing, Lionel
    TRANSPLANT INTERNATIONAL, 2024, 37
  • [25] PROTOCOL BIOPSIES IN PATIENTS WITH SUBCLINICAL DE NOVO DSA IN KIDNEY TRANSPLANTATION
    Bertrand, D.
    Jaureguy, M.
    Garrouste, C.
    Sayegh, J.
    Bouvier, N.
    Caillard, S.
    Lanfranco, L.
    Galinier, A.
    Fancois, A.
    Hau, F.
    Etienne, I.
    Gatault, P.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 25 - 25
  • [26] PHENOTYPIC STUDY OF KIDNEY TRANSPLANT PATIENTS PRESENTING DE NOVO DSA: A FRENCH MULTICENTER COHORT OF 96 CASES
    Lanfranco, L.
    Grall, A.
    Ohlmann, S.
    Presne, C.
    De Ligny, B. Hurault
    Villemain, F.
    Heng, E.
    Rerolle, J.
    Touchard, G.
    Snanoudj, R.
    Etienne, I.
    Toupance, O.
    Buchler, M.
    Gatault, P.
    Bertrand, D.
    Le Meur, Y.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 18 - 18
  • [27] De novo urologic tumors in kidney transplant patients
    Rodriguez Faba, O.
    Breda, A.
    Gausa, L.
    Palou, J.
    Villavicencio, H.
    ACTAS UROLOGICAS ESPANOLAS, 2015, 39 (02): : 122 - 127
  • [28] Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA
    Beland, M. -A.
    Noel, R.
    Cote, I.
    Lapointe, I.
    Wagner, E.
    Riopel, J.
    Latulippe, E.
    Desy, O.
    Beland, S.
    Houde, I.
    De Serres, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 268 - 268
  • [29] Pharmacokinetics of Sotrastaurin Combined With Tacrolimus or Mycophenolic Acid in De Novo Kidney Transplant Recipients
    Kovarik, John M.
    Steiger, Juerg U.
    Grinyo, Josep M.
    Rostaing, Lionel
    Arns, Wolfgang
    Dantal, Jacques
    Proot, Pieter
    Budde, Klemens
    TRANSPLANTATION, 2011, 91 (03) : 317 - 322
  • [30] Belatacept Vs. Tacrolimus: Clinical Outcomes in De Novo Kidney Transplant Recipients
    Wongsaroj, P.
    Kahwaji, J.
    Vo, A.
    Choi, J.
    Villicana, R.
    Peng, A.
    Jordan, S.
    TRANSPLANTATION, 2014, 98 : 457 - 457
12345